The Perception and Management of Drug Safety Risks

图书简介

In the past two decades public debate about the risks, benefits, and safety associated with drugs has intensified. Public disputes over risks are brought to court when individuals seek compensation for health problems attributed to a pharmaceutical product. The issue reaches legislatures and regulatory agencies when consumer advocates seek to influence the standards of drug usage. Front-page news tends to focus on accidents or other risk events with drugs. Drug risk and drug safety have become an important political issue. Drug regulat ory agencies have been instituted, and their responsibility has increased. The approval to market a drug is dependent on a set of sophisticated studies executed according to strict protocols and scientifically defined criteria. Drug surveillance activities have gained recognition, and reporting systems to identify drug safety problems have been strengthened. The understanding and management of drug safety is, nonetheless, beset by doubts, disagreements, and disputes. Conflict occurs over the significance of risk, the adequacy of evidence, the methodologies used to evaluate and measure risk, the standards that guide regulation, and the optimal means of communicating risk information to the public.

Opening Address.- I: Society and the Benefit/Risk Relationship.- 1. Acceptable Risk in Society.- 2. A Broad Framework for Confronting Health Risks.- 3. Communicating the Risks and Benefits of Technology: The Case of Pharmaceuticals.- 4. Overview of the Drug Safety Issue and Ciba-Geigy’s Response: RAD-AR.- 5. Summary of Part I: Presentations and Discussions.- II: Benefit/Risk Analysis and Appraisal.- 6. Limitations of Available Sources of Data on Prescription Drug Safety.- 7. Strategies, Designs, Criteria, Tactics and Statistics to be Considered when Evaluating Scientific Evidence.- 8. Statistics in Drug Risk Research: The Background of Pharmacoepidemiology.- 9. Industry-Sponsored Risk Institutes.- 10. The Feldene Experience: A Case Study.- 11. Risk Perception of Prescription Drugs: Report on a Survey in Sweden.- 12. Risk Perception of Prescription Drugs: Report on Surveys in Japan.- 13. Scientific and Political Components of Regulatory Decision Making: General Considerations.- 14. Scientific and Political Components of Regulatory Decision Making: The United States Experience.- 15. Summary of Part II: Presentations and Discussions.- III: Current Challenges.- 16. Professional Drug Information: A Consumer Perspective.- 17. Going Patient, Going Public.- 18. Reporting Adverse Drug Reactions: The Media Approach.- 19. What Can Be Learned from Drug Safety Issues?.- 20. Summary of Part III: Presentations and Discussions.- IV: Responding to the Issues.- 21. Editor’s Note.- 22. Pharmacoepidemiology.- 23. Risk Perception Analysis.- 24. Communicating the Benefit/Risk Relationship.- 25. Risk Appraisal on an International Scale.- V: Outlook.- 26. The Wolfsberg Questions.- VI: Annex.- 27. Curriculum Vitae of Authors.- 28. Bibliography.- 29. Subject Index.- 30. A Handbook of International Data Sources for Drug Benefit/Risk Assessment.

Trade Policy 买家须知

关于产品：
● 正版保障：本网站隶属于中国国际图书贸易集团公司，确保所有图书都是100%正版。
● 环保纸张：进口图书大多使用的都是环保轻型张，颜色偏黄，重量比较轻。
● 毛边版：即书翻页的地方，故意做成了参差不齐的样子，一般为精装版，更具收藏价值。
关于退换货：
由于预订产品的特殊性，采购订单正式发订后，买方不得无故取消全部或部分产品的订购。
由于进口图书的特殊性，发生以下情况的，请直接拒收货物，由快递返回：
● 外包装破损/发错货/少发货/图书外观破损/图书配件不全（例如：光盘等）
并请在工作日通过电话400-008-1110联系我们。
签收后，如发生以下情况，请在签收后的5个工作日内联系客服办理退换货：
● 缺页/错页/错印/脱线
关于发货时间：
一般情况下：
●【现货】下单后48小时内由北京（库房）发出快递。
●【预订】【预售】下单后国外发货，到货时间预计5-8周左右，店铺默认中通快递，如需顺丰快递邮费到付。
● 需要开具发票的客户，发货时间可能在上述基础上再延后1-2个工作日（紧急发票需求，请联系010-68433105/3213）；
● 如遇其他特殊原因，对发货时间有影响的，我们会第一时间在网站公告，敬请留意。
关于到货时间：
由于进口图书入境入库后，都是委托第三方快递发货，所以我们只能保证在规定时间内发出，但无法为您保证确切的到货时间。
● 主要城市一般2-4天
● 偏远地区一般4-7天
关于接听咨询电话的时间：
010-68433105/3213正常接听咨询电话的时间为：周一至周五上午8：30～下午5：00，周六、日及法定节假日休息，将无法接听来电，敬请谅解。
其它时间您也可以通过邮件联系我们：customer@readgo.cn,工作日会优先处理。
关于快递：
● 已付款订单：主要由中通、宅急送负责派送，订单进度查询请拨打010-68433105/3213。

The Perception and Management of Drug Safety Risks（Health Systems Research） 药理学

The Perception and Management of Drug Safety Risks（Health Systems Research）
药理学